Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Change in Acquisitions & Divestments (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Change in Acquisitions & Divestments for 5 consecutive years, with $10.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Acquisitions & Divestments changed 0.0% year-over-year to $10.0 million, compared with a TTM value of $75.0 million through Sep 2025, down 25.0%, and an annual FY2024 reading of $128.0 million, up 6.67% over the prior year.
  • Change in Acquisitions & Divestments was $10.0 million for Q3 2025 at Ovid Therapeutics, down from $17.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $60.0 million in Q4 2022 and bottomed at $10.0 million in Q4 2023.
  • Average Change in Acquisitions & Divestments over 4 years is $28.8 million, with a median of $30.0 million recorded in 2022.
  • The sharpest move saw Change in Acquisitions & Divestments crashed 83.33% in 2023, then soared 280.0% in 2024.
  • Year by year, Change in Acquisitions & Divestments stood at $60.0 million in 2022, then plummeted by 83.33% to $10.0 million in 2023, then skyrocketed by 280.0% to $38.0 million in 2024, then plummeted by 73.68% to $10.0 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for OVID at $10.0 million in Q3 2025, $17.0 million in Q2 2025, and $10.0 million in Q1 2025.